Weekly Recap: PDS0101+pembrolizumab Phase 2 OS and Nant Capital $22.3M PIPE
PDS Biotechnology Corp. (NASDAQ:PDSB) reported Phase 2 PDS0101+pembrolizumab results showing 39.3—month median OS in 1L ICI—naïve CPS≥1 patients, 36% ORR and 13.8% Grade≥3 TRAEs, while PDS0301 showed strong survival; the company closed up to $22.3M PIPE with Nant Capital and granted NantWorks a one…